Activation of the BRCA1/Chk1/p53/p21 Cip1/Waf1 pathway by nitric oxide and cell cycle arrest in human neuroblastoma NB69 cells

Nitric Oxide - Biology and Chemistry

Volumn 26, Issue 3, 2012, Pages 182-191

  Wouwer, Marlies Van De ^a   Couzinié, Célia ^a   Serrano Palero, Miguel ^a   González Fernández, Óscar ^a   Galmés Varela, Clara ^a   Menéndez Antolí, Paula ^a   Grau, Laura ^a   Villalobo, Antonio ^a  

^a CSIC   (Spain)

Author keywords

Apoptosis; Cell cycle; Cell proliferation; Neuroblastoma cells; Nitric oxide; p38MAPK

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BRCA1 PROTEIN; CHECKPOINT KINASE 1; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2D; CYCLIN E; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE DONOR; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

BRCA1 PROTEIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; NEUROBLASTOMA; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASES; PYRIDINES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859103642     PISSN: 10898603     EISSN: 10898611     Source Type: Journal    
DOI: 10.1016/j.niox.2012.02.003     Document Type: Article

References (58)

1. A.J. Gow, and H. Ischiropoulos Nitric oxide chemistry and cellular signaling J. Cell. Physiol. 187 2001 277 282
2. K.L. Davis, E. Martin, I.V. Turko, and F. Murad Novel effects of nitric oxide Annu. Rev. Pharmacol. Toxicol. 41 2001 203 236
3. A. Villalobo Nitric oxide and cell proliferation FEBS J. 273 2006 2329 2344
4. A. Villalobo Enhanced cell proliferation induced by nitric oxide Dyn. Cell Biol. 1 2007 60 64
5. C. Estrada, C. Gómez, J. Martín-Nieto, T. De Frutos, A. Jiménez, and A. Villalobo Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase Biochem. J. 326 1997 369 376
6. M.J. Ruano, S. Hernández-Hernando, A. Jiménez, C. Estrada, and A. Villalobo Nitric oxide-induced epidermal growth factor-dependent phosphorylations in A431 tumour cells Eur. J. Biochem. 270 2003 1828 1837
7. M. Murillo-Carretero, M.J. Ruano, E. Rodríguez-Matarredona, A. Villalobo, and C. Estrada Antiproliferative effect of nitric oxide on epidermal growth factor-responsive human neuroblastoma cells J. Neurochem. 83 2002 119 131
8. M. Murillo-Carretero, A. Torroglosa, C. Castro, A. Villalobo, and C. Estrada S-Nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity Free Radic. Biol. Med. 46 2009 471 479
9. O. González-Fernández, A. Jiménez, and A. Villalobo Differential p38 mitogen-activated protein kinase-controlled hypophosphorylation of the retinoblastoma protein induced by nitric oxide in neuroblastoma cells Free Radic. Biol. Med. 44 2008 353 366
10. K.D. Kroncke, V. Kolb-Bachofen, B. Berschik, V. Burkart, and H. Kolb Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation Biochem. Biophys. Res. Commun. 175 1991 752 758
11. P. Nicotera, E. Bonfoco, and B. Brüne Mechanisms for nitric oxide-induced cell death: involvement of apoptosis Adv. Neuroimmunol. 5 1995 411 420
12. P. Andréka, T. Tran, K.A. Webster, and N.H. Bishopric Nitric oxide and promotion of cardiac myocyte apoptosis Mol. Cell. Biochem. 263 2004 35 53
13. H.P. Monteiro, E.F. Silva, and A. Stern Nitric oxide: a potential inducer of adhesion-related apoptosis-anoikis Nitric Oxide 10 2004 1 10
14. C.Q. Li, and G.N. Wogan Nitric oxide as a modulator of apoptosis Cancer Lett. 226 2005 1 15
15. S.Y. Olson, and H.J. Garbán Regulation of apoptosis-related genes by nitric oxide in cancer Nitric Oxide 19 2008 170 176
16. L. Leon, J.F. Jeannin, and A. Bettaieb Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis Nitric Oxide 19 2008 77 83
17. M. Van de Wouwer, S. André, H.-J. Gabius, and A. Villalobo Nitric oxide changes distinct aspects of the glycophenotype of human neuroblastoma NB69 cells Nitric Oxide 24 2011 91 101
18. N.S. Bryan, K. Bian, and F. Murad Discovery of the nitric oxide signaling pathway and targets for drug development Front. Biosci. 14 2009 1 18
19. J.C. Drapier, and C. Bouton Modulation by nitric oxide of metalloprotein regulatory activities BioEssays 18 1996 549 556
20. D.T. Hess, A. Matsumoto, S.-O. Kim, H.E. Marshall, and J.S. Stamler Protein S-nitrosylation: purview and parameters Nat. Rev. Mol. Cell Biol. 6 2005 150 166
21. P. Pacher, J.S. Beckman, and L. Liaudet Nitric oxide and peroxynitrite in health and disease Physiol. Rev. 87 2007 315 424
22. M.R. Miller, and I.L. Megson Recent developments in nitric oxide donor drugs Br. J. Pharmacol. 151 2007 305 321
23. J.A. Coulter, H.O. McCarthy, J. Xiang, W. Roedl, E. Wagner, T. Robson, and D.G. Hirst Nitric oxide - a novel therapeutic for cancer Nitric Oxide 19 2008 192 198
24. P. Sonveaux, B.F. Jordan, B. Gallez, and O. Feron Nitric oxide delivery to cancer: why and how? Eur. J. Cancer 45 2009 1352 1369
25. D. Fukumura, S. Kashiwagi, and R.K. Jain The role of nitric oxide in tumour progression Nat. Rev. Cancer 6 2006 521 534
26. E. Peña-Altamira, P. Petazzi, and A. Contestabile Nitric oxide control of proliferation in nerve cells and in tumor cells of nervous origin Curr. Pharm. Des. 16 2010 440 450
27. W. Badn, and P. Siesjö The dual role of nitric oxide in glioma Curr. Pharm. Des. 16 2010 428 430
28. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
29. Y. Chen, A.A. Farmer, C.F. Chen, D.C. Jones, P.L. Chen, and W.H. Lee BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner Cancer Res. 56 1996 3168 3172
30. R. Scully, J. Chen, R.L. Ochs, K. Keegan, M. Hoekstra, J. Feunteun, and D.M. Livingston Dynamic changes of BRCA1 subnuclear location and phosphorylation state are indicated by DNA damage Cell 90 1997 425 435
31. R. Yuan, S. Fan, J.-A. Wang, Q. Meng, Y. Ma, D. Schreiber, I.D. Goldberg, and E.M. Rosen Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells Prostate 40 1999 37 49
32. A.D. Choudhury, H. Xu, and R. Baer Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression J. Biol. Chem. 279 2004 33909 33918
33. M.V. Blagosklonny, W.G. An, G. Melillo, P. Nguyen, J.B. Trepel, and L.M. Neckers Regulation of BRCA1 by protein degradation Oncogene 18 1999 6460 6468
34. Y.H. Choi Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells Int. J. Oncol. 19 2001 687 693
35. C.C. Franklin, and A.S. Kraft Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells J. Biol. Chem. 272 1997 16917 16923
36. L.E. Giono, and J.J. Manfredi The p53 tumor suppressor participates in multiple cell cycle checkpoints J. Cell. Physiol. 209 2006 13 20
37. M. Nakanishi, M. Shimada, and H. Niida Genetic instability in cancer cells by impaired cell cycle checkpoints Cancer Sci. 97 2006 984 989
38. B. Derijard, J. Raingeaud, T. Barrett, I.H. Wu, J. Han, R.J. Ulevitch, and R.J. Davis Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms Science 267 1995 682 685
39. J. Han, J.D. Lee, Y. Jiang, Z. Li, L. Feng, and R.J. Ulevitch Characterization of the structure and function of a novel MAP kinase kinase (MKK6) J. Biol. Chem. 271 1996 2886 2891
40. A.J. Thompson, P.K. Mander, and G.C. Brown The NO donor DETA-NONOate reversibly activates an inward current in neurones and is not mediated by the released nitric oxide Br. J. Pharmacol. 158 2009 1338 1343
41. T.W. Owens, A.J. Valentijn, J.P. Upton, J. Keeble, L. Zhang, J. Lindsay, N.K. Zouq, and A.P. Gilmore Apoptosis commitment and activation of mitochondrial Bax during anoikis is regulated by p38MAPK Cell Death Differ. 16 2009 1551 1562
42. A. Vázquez, E.E. Bond, A.J. Levine, and G.L. Bond The genetics of the p53 pathway, apoptosis and cancer therapy Nat. Rev. Drug Discov. 7 2008 979 987
43. S. Kumar, M. Kumar Barthwal, and M. Dikshit Cdk2 nitrosylation and loss of mitochondrial potential mediate NO-dependent biphasic effect on HL-60 cell cycle Free Radic. Biol. Med. 48 2010 851 861
44. K. Takagi, Y. Isobe, K. Yasukawa, E. Okouchi, and Y. Suketa Nitric oxide blocks the cell cycle of mouse macrophage-like cells in the early G2+M phase FEBS Lett. 340 1994 159 162
45. A. Jarry, L. Charrier, C. Bou-Hanna, M. Devilder, V. Crussaire, M.G. Denis, G. Vallette, and C.L. Laboisse Position in the cell cycle controls the sensitivity of colon cancer cells to nitric oxide-dependent programmed cell death Cancer Res. 64 2004 4227 4234
46. X. Cui, J. Zhang, P. Ma, D. Myers, I.G. Goldberg, K.J. Sitttler, J.J. Barb, P.J. Munson, A. del Pilar Cintron, J.P. McCoy, S. Wang, and R.L. Danner cGMP-independent nitric oxide signaling and regulation of the cell cycle BMC Genomics 6 2005 151 168
47. A. Tesei, L. Ricotti, P. Ulivi, L. Medri, D. Amadori, and W. Zoli NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines Int. J. Oncol. 22 2003 1297 1302
48. S. Huguenin, J. Fleury-Feith, L. Kheuang, M.-C. Jaurand, M. Bolla, J.-P. Riffaud, D.K. Chopin, and F. Vacherot Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines Prostate 61 2004 132 141
49. M.S.Y. Huen, S.M.H. Sy, and J. Chen BRCA1 and its toolbox for the maintenance of genome integrity Nat. Rev. Mol. Cell Biol. 11 2010 138 148
50. S. Burney, J.L. Caulfield, J.C. Niles, J.S. Wishnok, and S.R. Tannenbaum The chemistry of DNA damage from nitric oxide and peroxynitrite Mutat. Res. 424 1999 37 49
51. T. Nakano, H. Terato, K. Asagoshi, A. Masaoka, M. Mukuta, Y. Ohyama, T. Suzuki, K. Makino, and H. Ide DNA-protein cross-link formation mediated by oxanine: a novel genotoxic mechanism of nitric oxide-induced DNA damage J. Biol. Chem. 278 2003 25264 25272
52. G.M. Cahuana, J.R. Tejedo, J. Jiménez, R. Ramírez, F. Sobrino, and F.J. Bedoya Nitric oxide-induced carbonylation of Bcl-2, GAPDH and ANT precedes apoptotic events in insulin-secreting RINm5F cells Exp. Cell Res. 293 2004 22 30
53. A.N. Kong, E. Owuor, R. Yu, V. Hebbar, C. Chen, R. Hu, and C. Mandlekar Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE) Drug Metab. Rev. 33 2001 255 271
54. H. Muniyappa, and K.C. Das Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism Cell. Signal. 20 2008 675 683
55. M. Hirosawa, M. Nakahara, R. Otosaka, A. Imoto, T. Okazaki, and S. Takahashi The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells Leuk. Res. 33 2009 693 699
56. C. Huang, W.Y. Ma, A. Maximer, Y. Sun, and Z. Dong p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389 J. Biol. Chem. 274 1999 12229 12235
57. D.V. Bulavin, S. Saito, M.C. Hollander, K. Sakaguchi, C.W. Anderson, E. Appella, and A.J. Fornace Jr. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation EMBO J. 18 1999 6845 6854
58. M.R. Kibbe, J. Li, S. Nie, S.C. Watkins, A. Lizonova, I. Kovesdi, R.L. Simmons, T.R. Billiar, and E. Tzeng Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate J. Vasc. Surg. 31 2000 1214 1228